12th May 2023 09:39
Oxford Nanopore Technologies PLC - Oxford, England-based company that develops and sells nanopore sequencing products - Signs a definitive deal with PathoQuest SAS to co-develop an 'integration site analysis' test. Says the test will provide a good manufacturing practice validated nanopore sequencing-based commercial testing service to the biopharma industry. Oxford Nanopore says the service is designed to address the needs of industrial developers and manufacturers of biological products.
Oxford Nanopore Chief Executive Officer Gordon Sanghera says: "We are pleased to announce the next step of our partnership with PathoQuest, and we are excited to start on the development of this breakthrough test for biologics manufacturing. Nanopore sequencing offers a transformational new approach for robust and accurate genetic characterisation of biological materials, which we believe will enable the release of novel therapeutics with more certainty and safety assurance than ever before."
Current stock price: 247.60 pence each, down 0.7% on Friday morning in London
12-month change: down 2.7%
By Xindi Wei, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
Oxford Nano